Everything tagged "nasdaq" across the TickerSpark archives.
Vogenx Inc Common Stock is expected to list on NASDAQ on 2026-08-12, but the price range has not been disclosed. The company is a clinical-stage biopharma name focused on metabolic disorders, including post-bariatric hypoglycemia and gastroparesis. The setup favors investors who want an early-stage catalyst story, but shareholders should watch the capital needs and clinical risk closely.
Pelican Acquisition II Corporation Right (NASDAQ: PLCIR) is expected to list on 2026-08-12, but the price range has not been disclosed yet. This is a SPAC/right offering, not an operating company IPO, so the key question is whether the sponsor can source a credible technology deal. Watch the trust structure and dilution; the setup favors investors who are comfortable underwriting a blank-check search process.
Collective Mining Ltd. is expected to list on NASDAQ on 2026-08-11, but the price range has not been disclosed. The company is a pre-revenue Colombia-focused explorer, so the setup hinges on drilling progress, funding needs, and whether Apollo keeps delivering. Investors should watch for how much capital is being raised and how the market values the next phase of exploration.
Southern Cross Acquisition II Corp. (NASDAQ: SCATU) is expected to list on 2026-08-12 at a price range of $10.00 per unit. The offering is for 10,000,000 units, with a disclosed market cap of $115,000,000. The setup hinges on whether investors want a China-linked SPAC team with a blank-check mandate and no operating business yet.
Phosphate Holdings, Inc. (NASDAQ: PHOS) is expected to list on 2026-08-10, but the price range has not been disclosed. The company has not yet provided shares offered or a market cap. The setup favors a commodity-linked fertilizer story, but shareholders should watch for pricing, float, and whether this is a real new issue or a stale filing reference.
Siyata PTT is expected to list on NASDAQ on 2026-09-08, but the price range has not been disclosed yet. The company plans to offer 6,112,327 shares. Watch whether investors focus on its enterprise push-to-talk growth story or the going-concern and dilution risks that still hang over the business.
BioStem Technologies, Inc. (NASDAQ: BSEM) is expected to list on 2026-08-07, but the price range has not been disclosed. The company is coming to market through an expected Nasdaq uplisting rather than a traditional IPO prospectus. The bull case is a high-margin wound-care platform; the bear case is heavy customer concentration and a 2025 revenue drop.
QVC Group, Inc. Common Stock is expected to list on NASDAQ on 2026-08-06, but the price range has not been disclosed. The key question is whether this is a real IPO setup or a restructuring-driven market event. Bull case: a large, recognizable commerce brand with a multichannel audience; bear case: heavy debt, bankruptcy risk, and no disclosed pricing terms.
River City Bank is expected to list on NASDAQ on 2026-08-06, but the price range has not been disclosed. The key question is whether investors are buying a long-established Sacramento niche lender or a bank IPO with too little public filing detail to underwrite cleanly.
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is expected to list on 2026-08-05, but the price range has not been disclosed. The company plans to offer 17,000,000 shares. The setup is attractive if investors want early-stage immunology exposure, but the story still depends on clinical execution and funding discipline.
Latigo Biotherapeutics, Inc. (NASDAQ: LTGO) is expected to list on 2026-08-07 at a price range of $16.00 to $18.00 per share. The company is offering 16,000,000 shares, with a disclosed market cap of $331.2 million. The bull case is a differentiated non-opioid pain platform; the bear case is a clinical-stage biotech with no revenue, rising losses, and a long road to approval.
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) is expected to list on 2026-08-07 at a price range of $15.00 to $17.00 per share. The company is offering 7,812,500 shares, implying a market cap of $152,734,375 if priced at the midpoint assumptions provided. The bull case is a focused oncology pipeline with named clinical programs and a seasoned drug-discovery team. The bear case is straightforward: no product revenue, rising losses, and a going-concern warning if it cannot raise more capital.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime